EAPI Share Price Performance
€0
-2.72 (-100.00%)
Price €0
Fair Value€2.00
Share Pricen/a
Narrative Update • May 10
Euroapi S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
EAPI Community Narratives
AN
Fair Value
·Fair Value €2 27.4% undervalued intrinsic discount
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value €1 45.2% overvalued intrinsic discount
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €2.9 49.9% undervalued intrinsic discount
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
Key Takeaways Investments in capacity expansion, innovation, and premium CDMO projects position Euroapi for increased high-value API market share and resilient, higher-margin revenue growth. Structural cost reductions, site divestments, and regionalization trends are expected to strengthen profitability, operating efficiency, and long-term earnings stability.Read more
AN
€2
27.4% undervalued intrinsic discount
Fair Value
Profit Margin
1.72%
Future PE
15.56x
Price in 2029
€2.41
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
Key Takeaways Intensifying regulatory pressures and global deglobalization trends threaten profitability and export-driven growth, especially amid shifting mandates for local drug production. Heavy reliance on a few key clients and shrinking demand for traditional APIs expose the company to heightened revenue volatility and margin pressure.Read more
AN
€1
45.2% overvalued intrinsic discount
Fair Value
Profit Margin
0.27%
Future PE
51.39x
Price in 2029
€1.2
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
Key Takeaways Aggressive cost-cutting, advanced API technology, and government subsidies position Euroapi for substantial, sustained margin and revenue growth far beyond consensus expectations. Strategic expansion in both European and emerging markets, combined with a focus on high-value clients, strengthens global market share and ensures durable, compounding cash flows.Read more
AN
€2.9
49.9% undervalued intrinsic discount
Fair Value
Profit Margin
3.4%
Future PE
10.14x
Price in 2029
€3.46
Trending Discussion
Recently Updated Narratives
AN
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Fair Value: €2 27.4% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Fair Value: €1 45.2% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Fair Value: €2.9 49.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Euroapi S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 28, 2026
- -2.22
- 17.00%
- -24.77%
- 5.8%
About EAPI
- Founded
- 2020
- Employees
- 2961
- CEO
- WebsiteView website
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Recent EAPI News & Updates
Narrative Update • Apr 22
